Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.35 |
| ▸ | VEGFA | P15692 | 2/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198083 | 0.89 | GLA (0.39) | HTTEPAS1CCR5ALDH1A1LRRK2 | |
| SCHEMBL7183011 | 0.88 | PTPN1 (0.38) | PTPN1MAOBMAOAALDH1A1 | |
| SCHEMBL7193736 | 0.88 | PTPN1 (0.38) | PTPN1EPAS1MAOBMAOACCR5 | |
| SCHEMBL7599756 | 0.86 | PTPN1 (0.39) | HTTPTPN1ALDH1A1 | |
| SCHEMBL7592992 | 0.85 | LMNA (0.38) | HTTPTPN1EPAS1ALDH1A1 | |
| SCHEMBL7188724 | 0.84 | PTPN1 (0.42) | PTPN1MAOBMAOAALDH1A1 | |
| SCHEMBL7598764 | 0.84 | PTPN1 (0.37) | PTPN1 | |
| SCHEMBL7595556 | 0.84 | TP53 (0.37) | PTPN1ALDH1A1 | |
| SCHEMBL7195289 | 0.83 | HTT (0.40) | HTTPTPN1ALDH1A1 | |
| SCHEMBL7193735 | 0.83 | PTPN1 (0.35) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | claimed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | HTT 1549/4885PTPN1 13/4885VEGFA 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.